238 related articles for article (PubMed ID: 28533049)
1. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
2. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
[TBL] [Abstract][Full Text] [Related]
4. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF
Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386
[TBL] [Abstract][Full Text] [Related]
5. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
[TBL] [Abstract][Full Text] [Related]
8. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
[TBL] [Abstract][Full Text] [Related]
9. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
10. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
[TBL] [Abstract][Full Text] [Related]
13. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
[TBL] [Abstract][Full Text] [Related]
14. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
18. Rates of change in FEV
Taveira-DaSilva AM; Julien-Williams P; Jones AM; Stylianou M; Moss J
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519926
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
20. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
